Capsule Summary Slidesets

Share

Program Content

Activities

  • P011: ISL + DOR
    Phase IIb Protocol 011: Islatravir Plus Doravirine Following Islatravir, Doravirine, Lamivudine Induction in Treatment-Naive Patients Demonstrates Very Low HIV-1 RNA Levels in Patients With Wk 48 Protocol-Defined Virologic Failure
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 05, 2020

    Expires: July 04, 2021

  • AIR Study
    AIR: No Impact of Switching From 3-Drug to 2-Drug ART on Adverse Disease Outcomes in Virologically-Suppressed Persons With HIV
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 10, 2020

    Expires: July 09, 2021

  • BIC/FTC/TAF in Older Patients
    Pooled Wk 48 Analysis of Switch to BIC/FTC/TAF in Virologically Suppressed Patients Aged 65 Yrs or Older
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 11, 2020

    Expires: July 10, 2021

  • OPERA
    OPERA: Excess Weight Gain Observed Immediately After Switch From TDF to TAF in Virologically Suppressed Adults Regardless of INSTI Use
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 10, 2020

    Expires: July 09, 2021

  • DRIVE-SHIFT
    DRIVE-SHIFT: Modest Weight Gain Observed Through Wk 144 After Switch to DOR/3TC/TDF in Virologically Suppressed Adults
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 10, 2020

    Expires: July 09, 2021

  • TANGO
    TANGO: Metabolic Parameters Improve at Wk 48 Following Switch to DTG/3TC, Especially From Boosted Baseline ART
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 11, 2020

    Expires: July 10, 2021

  • ADVANCE Wk 96
    Phase III ADVANCE: 96-Wk Primary Efficacy Analysis of DTG + FTC/(TAF or TDF) vs EFV/FTC/TDF in ART-Naive PWH in South Africa
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 10, 2020

    Expires: July 09, 2021

  • HPTN 083: LA Cabotegravir
    HPTN 083: Long-Acting Injectable CAB Superior to Daily Oral TDF/FTC as PrEP in MSM and TGW at High Risk of HIV Infection
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 11, 2020

    Expires: July 10, 2021

  • Tsepamo 2020 Update
    Tsepamo: DTG Exposure at Conception Associated With Small but Stabilizing Elevation in Neural Tube Defect Prevalence in Analysis Through April 2020
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 11, 2020

    Expires: July 10, 2021

  • Lenacapavir Phase I
    Phase I Pharmacokinetic Study of Novel HIV-1 Capsid Inhibitor Lenacapavir Supports Potential for Every-6-Month SC Dosing
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 10, 2020

    Expires: July 09, 2021

Provided by

ProCE Banner

Supporters

Gilead

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

AIDS 2020

ProCE Banner

IAS 2018

ProCE Banner